Clareo Health | A Study to Evaluate the Efficacy and Safety of Quinapril or Quinapril Plus Hydrochlorothiazide in Patients With Mild to Moderate Hypertension
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
19–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
A clinical diagnosis of mild to moderate primary hypertension ("Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, 6th report" Stage I or II)
Sitting diastolic blood pressure between 90 mmHg and 109 mmHg and systolic blood pressure between 140 mmHg and 179 mmHg at the end of the no-treatment run-in period
You may not be if
Subjects with secondary hypertension
Subjects with serious cardiac disease (including myocardial infarction in the last 3 months or decompensated heart failure)
Subjects who do not accept to stop using any other antihypertensive treatment during the run-in period and the treatment period of the study
